About Stoic Bio

David Sheehan is the Founder, President, and CEO of Stoic Bio. He has led the development of novel capital equipment that radically changes the delivery of cell culture media, with a focus on sustainability. Prior to Stoic Bio, Dave was COO of Volcano Corporation, a publicly held life sciences company that was sold to Philips for $1.2 billion. Previous to Volcano, Dave was the CEO of Digirad, a cardiovascular imaging company that he took public in 2004, and in leadership positions at Baxter and Haemonetics. Dave also founded and is currently the CEO of Nucleus Biologics, (Stoic Bio's sister company), where he leads the development of innovative cell culture tools to simplify and accelerate the design, customization, and ordering of cell culture media products. Dave holds an MBA from The Tuck School at Dartmouth College and a BS in Mechanical Engineering from Worcester Polytechnic Institute.

Will has over 30 years of experience in financial and business leadership roles across a diverse range of industries, including wireless technologies, internet of things devices, and cosmeceuticals. Will serves as CFO for both Stoic Bio and sister company Nucleus Biologics. Previously, Will was the Senior VP of Finance and Operations for SENTE, and before that, was the CFO of LocusTraxx, leading the company to a successful acquisition exit. Will also spent 12 years at Qualcomm in various leadership roles across multiple divisions including new business development, finance lead for the successful acquisition of a business from Alcatel, and leading international finance and business operations for Qualcomm’s Omnitracs division. Will has a BS degree in accounting from Purdue University and an MBA in Finance with honors from the University of North Texas.

Rob Friel served as the chairman and chief executive officer of PerkinElmer, a global leader in life sciences with a mission of innovating for a healthier world, from February, 2008 until his retirement in December 2019. From August 2007 to January, 2019, Mr. Friel also served as PerkinElmer's president. Since joining PerkinElmer in February 1999 as chief financial officer, Mr. Friel also held roles as chief operating officer and president of PerkinElmer's life and analytical sciences unit. Prior to joining PerkinElmer, he held senior management positions with AlliedSignal, now Honeywell International. Mr. Friel currently serves as a member of the board of directors of West Pharmaceutical Services, NuVasive, New York Life, and chairman of the board of directors of Xylem. He also is an advisor to EQT Private Equity. Mr. Friel received a bachelor's degree from Lafayette College and a master's degree from Fairleigh Dickinson University.